BUSINESS SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, ACOs, and DCEs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2021, 2020 and 2019.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.

    As of December 31, 2021, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the years ended December 31, 2021, 2020 and 2019. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.

	2021		2020		2019
Net revenues:
DIS business	$	10,494	$	9,139	$	7,405
All other operating segments	294		298		321
Total net revenues	$	10,788	$	9,437	$	7,726
Operating earnings (loss):
DIS business	$	2,646	$	2,201	$	1,298
All other operating segments	29		39		42
General corporate activities	(294)		(269)		(109)
Total operating income	2,381		1,971		1,231
Non-operating income (expense), net	218		(87)		(155)
Income from continuing operations before income taxes and equity in earnings of equity method investees	2,599		1,884		1,076
Income tax expense	(597)		(460)		(247)
Equity in earnings of equity method investees, net of taxes	78		75		57
Income from continuing operations	2,080		1,499		886
Income from discontinued operations, net of taxes	—		—		20
Net income	2,080		1,499		906
Less: Net income attributable to noncontrolling interests	85		68		48
Net income attributable to Quest Diagnostics	$	1,995	$	1,431	$	858

    Depreciation and amortization expense for the years ended December 31, 2021, 2020 and 2019 were as follows:

	2021		2020		2019
DIS business	$	294	$	249	$	226
All other operating segments	10		8		6
General corporate	104		104		97
Total depreciation and amortization	$	408	$	361	$	329

    Capital expenditures for the years ended December 31, 2021, 2020 and 2019 were as follows:

	2021		2020		2019
DIS business	$	379	$	394	$	373
All other operating segments	14		15		20
General corporate	10		9		7
Total capital expenditures	$	403	$	418	$	400

    Net revenues by major service for the years ended December 31, 2021, 2020 and 2019 were as follows:

	2021		2020		2019
Routine clinical testing and other services	$	4,293	$	3,836	$	4,206
COVID-19 testing services	2,770		2,723		—
Gene-based and esoteric (including advanced diagnostics) testing services	2,878		2,098		2,620
Anatomic pathology testing services	553		482		579
All other	294		298		321
Total net revenues	$	10,788	$	9,437	$	7,726